60 results
8-K
EX-99.1
COCP
Cocrystal Pharma, Inc.
14 Aug 24
Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
research organization (CROs) and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed
8-K
EX-99.1
COCP
Cocrystal Pharma, Inc.
13 May 24
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:15am
organization (CROs) and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed with, clinical
8-K
EX-99.1
0azry s5pz133bn
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
8-K
EX-99.1
g0e2s882x
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
8-K
EX-99.1
b7n461 u75del
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
h7afi
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
x3jlihi
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
xp33577b7dgrtqgmf54
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
kqbnr19izjon7c1zuzcv
24 Apr 23
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
8:13am
8-K
EX-99.1
upveug107hvzntc8wk
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am